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Background: Physicians often do not initiate or intensify treatments when clearly war-
ranted, a phenomenon known as therapeutic inertia (TI). Limited information is available 
on educational interventions to ameliorate knowledge-to-action gaps in TI.
Objectives: To evaluate the feasibility and efficacy of an educational intervention 
compared to usual care among practicing neurologists caring for patients with multiple 
sclerosis (MS).
Methods: We conducted a pilot double-blind, parallel-group, randomized clinical 
trial. Inclusion criteria included neurologists who are actively involved in managing 
MS patients. Participants were exposed to 20 simulated case-scenarios (10 cases at 
baseline, and 10 cases post-randomization to usual care vs. educational intervention) 
of relapsing–remitting MS with moderate or high risk of disease progression. The edu-
cational intervention employed a traffic light system (TLS) to facilitate decisions, allowing 
participants to easily recognize high-risk scenarios requiring treatment escalation. We 
also measured differences between blocks to invoke decision fatigue. The control group 
responded as they would do in their usual clinical practice not exposed to the educa-
tional intervention. The primary feasibility outcome was the proportion of participants 
who completed the study and the proportion of participants who correctly identified 
a high-risk case-scenario with the “red traffic light.” Secondary outcomes included 
decision fatigue (defined as an increment of TI in the second block of case-scenarios 
compared to the first block) and the efficacy of the educational intervention measured 
as a reduction in TI for MS treatment.
results: Of 30 neurologists invited to be part of the study, the participation rate was 
83.3% (n = 25). Of the 25 participants, 14 were randomly assigned to the control group 
and 11 to the intervention group. TI was present in 72.0% of participants in at least one 
case scenario. For the primary feasibility outcome, the completion rate of the study 
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was 100% (25/25 participants). Overall, 77.4% of participants correctly identified the 
“red traffic light” for clinical-scenarios with high risk of disease progression. Similarly, 
86.4% of participants correctly identified the “yellow traffic light” for cases that would 
require a reassessment within 6–12 months. For the secondary fatigue outcome, with-
in-group analysis showed a significant increased prevalence of TI in the second block of 
case-scenarios (decision fatigue) among participants randomized to the control group 
(TI pre-intervention 57.1% vs. TI post-intervention 71.4%; p =  0.015), but not in the 
active group (TI pre-intervention 54.6% vs. TI post-intervention 63.6%; p = 0.14). For the 
efficacy outcome, we found a non-significant reduction in TI for the targeted intervention 
compared to controls (22.6 vs. 33.9% post-intervention; OR 0.57; 95% CI 0.26–1.22).
Conclusion: An educational intervention applying the TLS is feasible and shows some 
promising results in the identification of high-risk scenarios to reduce decision fatigue 
and TI. Larger studies are needed to determine the efficacy of the proposed educational 
intervention.
Clinical Trial registration: www.ClinicalTrials.gov, identifier NCT03134794.
Keywords: multiple sclerosis, disease-modifying therapy, neuroeconomics, decision making, risk aversion
BaCKGrOUnD
Despite significant therapeutic advances, many patients remain 
undertreated, especially those with chronic medical conditions, 
such as atrial fibrillation, hypertension, and multiple sclerosis 
(MS) (1–4). One of the explanations relates to knowledge integra-
tion and knowledge-to-action gaps in therapeutic decisions. For 
example, it is known that physicians can be aware and informed 
about the current management of the common medical condi-
tions they see in their daily clinical practice, but fail to integrate 
available information (e.g., severity of the condition, risk of 
progression, imaging findings, demographic factors affecting 
outcomes) and to implement best practice recommendations 
based on the available knowledge. This phenomenon may lead to 
therapeutic inertia (TI) usually associated with poorer outcomes 
(2–4). TI is a term that defines the absence of treatment initiation 
or intensification in patients when treatment goals are unmet. 
It affects 30–70% of clinicians caring for patients with chronic 
conditions (2, 5–7). Physician factors (e.g., low tolerance to 
uncertainty, status quo bias) are considered to be the main con-
tributors to TI, but remain poorly studied (8–10).
Given physicians’ limited training in risk management and 
formal learning in medical decision-making, educational inter-
ventions could optimize medical decisions (11). Previous research 
suggests that such interventions can improve medical decisions. 
A meta-analysis comprising 609 eligible studies enrolling 35,226 
trainees compared the efficacy of simulation-based educational 
interventions (e.g., case-scenarios) in clinical skills and medical 
decision-making. The authors showed that a simulation-based 
educational intervention was more effective than standard edu-
cational programs for outcomes of knowledge, skills, and trainee’s 
behavior (12). Other studies using a simulation-based interven-
tion and clinical reasoning revealed a reduction in medical errors 
(13, 14). We have scarce information on strategies to overcome TI 
and only little evidence is available regarding effective educational 
interventions to reduce “knowledge-to-action” gaps.
The traffic light system (TLS) is an strategy that facilitates the 
decision-making process using traffic light terminology to match 
three types of situations: red light (“high risk”/“stop and think”), 
yellow light (warning), and green light (“stable”/“continue the 
same strategy”). The TLS emerged as a warning and risk cat-
egorization strategy to reduce human errors (15). It relies in a 
“hard-wired” cross-cultural color-coded concept that facilitates 
the integration of specific situations with an action (16–18). For 
example, studies showed that the TLS facilitated healthier food 
choices by interfering with automatic decisions and triggering re-
evaluation processes (19). We focus on MS because of the broad 
availability of therapeutic options and clear definitions (clinical 
and radiological) of disease activity as the accepted criteria to 
escalate treatment.
We hypothesized that an educational intervention using 
the TLS may be feasible and effective to overcome insufficient 
knowledge integration and knowledge-to action gaps in the man-
agement of MS. In the present study, we evaluated the feasibility 
of an educational intervention to identify clinical situations of 
moderate and high risk of disease progression that may lead to 
TI. Our intervention was designed following the results of our 
previous studies on TI in MS care (4, 20).
METHODS
Study Design and Participants
This pilot, double-blinded, parallel-group, randomized clinical 
trial evaluated the feasibility of an educational intervention (active 
group) compared to usual care (control group) in the manage-
ment of MS (Figure 1—CONSORT flow diagram). The goal of the 
education intervention was to facilitate risk stratification-action 
FiGUrE 1 | CONSORT flow diagram.
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gaps in MS care. We expected the TLS would facilitate the iden-
tification of high-risk clinical-scenarios (i.e., “red” in the TLS) 
leading to assertive therapeutic decisions (e.g., escalate therapy 
when appropriate). Inclusion criteria included neurologists who 
were actively involved in managing MS patients. Physicians 
whose practice was primarily in caring for MS patients were clas-
sified as “MS specialists.”
Candidates were invited to participate in a face-to-face meet-
ing held in Madrid, Spain. The recruitment of participants was 
facilitated by the Spanish Neurological Society. We targeted the 
first 30 participants who replied to an e-mail invitation from a 
pool of neurologists who met the inclusion criteria. The study 
was conducted using Qualtrics, a web-based platform (www.
Qualtrics.com). Each participant was provided with a tablet PC 
to complete the study. Participants were randomized (1:1 ratio), 
an automatic process in Qualtrics. Allocation concealment 
was facilitated in Qualtrics, so participants did not know what 
intervention will be allocated to after completing the 10 initial 
case-scenarios.
The study comprised 20 MS case-scenarios (see Appendix). 
Participants were exposed to 10 baselines case-scenarios (Block 1). 
Then, participants were randomized to usual care vs. educational 
intervention (TLS) followed by 10 additional similar case-
scenarios (Block 2). In-line with the learning and education 
literature, case-vignettes, clinical scenarios, or “real world” 
encounters are regarded as the best simple strategy to evaluate 
cognitive biases among physicians (21, 22).
Case-scenarios were designed by our research team and MS 
experts (Angel P. Sempere, Gustavo Saposnik, Jorge Maurino, 
and Xavier Montalban). Overall, 16 cases were designed to assess 
appropriate escalation of treatment (absence of treatment escala-
tion corresponding to TI; cases # 1–5, 8–10, 11–15, and 18–20), 
whereas the remaining four cases (case # 6, 7, 16, and 17) were 
designed to assess overtreatment (treatment escalation when there 
was no evidence of disease activity). Participants randomized 
to the intervention group (TLS) were also asked to identify the 
appropriate traffic light that would match the case-scenario. That 
question was prior to the selection of the therapeutic option.
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In Block 2, eight cases corresponded to clinical situations of 
high risk of MS progression, which participants in the interven-
tion group should associate with the “red traffic light,” whereas 
two cases were associated with moderate risk of progression 
requiring a re-assessment in a 6- to 12-month period, which 
participants should associate with the “yellow traffic light” 
(see Figures 2 and 3).
Data management, research coordination, and statistical 
analyses were conducted at the Li Ka Shing Knowledge Institute 
of St. Michael’s Hospital, Toronto. Operational procedures, 
guidelines for the implementation of both arms of the study, and 
the consent form were approved by the ethics review board at 
St. Michael’s Hospital, University of Toronto. Online informed 
consent was obtained from all participants. The study was 
conducted in Spanish. Participants received compensation for 
transportation. Further details of the protocol were published in 
www.ClinicalTrials.gov # NCT03134794 and elsewhere (20).
rationale and Description  
of the interventions
The current evidence suggests that medical decisions leading to 
TI are likely related to knowledge-to-action gaps (23, 24). We 
developed a simulation-based educational intervention aimed 
FiGUrE 2 | Continued
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at facilitating the integration of knowledge and overcoming 
knowledge-to-action gaps in MS care (25). The action component 
is the therapeutic decision (e.g., continue on the same treatment, 
change to a treatment that would not affect the clinical course or 
escalating to a more effective agent). We followed the Guideline for 
Reporting of Evidence-based practice Educational interventions 
and Teaching (GREET) statement to describe our educational 
intervention (Figure 2) (26).
Educational intervention: The TlS
Our study included two phases: pre-intervention and post-
intervention periods (Figure  3). Participants were randomly 
assigned to the educational intervention or control groups after 
the pre-intervention period.
Our educational intervention is based on the application of 
the TLS to medical decision-making (16–19, 27). In our study, 
the TLS was applied to help participants identify high-risk 
FiGUrE 2 | Continued
FiGUrE 2 | Description of the educational intervention according to the GREET guidelines.
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cases-scenarios, where MS patients had both clinical and radio-
logical activity. Consequently, participants should be able to 
identify the “red” traffic light and escalate treatment. The “yellow” 
represents caution when MS patients had either a clinical relapse 
or some degree of activity on brain imaging (but not both), which 
requires a reassessment within 6–12 months.
The control group made therapeutic decisions without being 
exposed to the educational intervention as part of the current 
standard practice. They had the option to take a break or continue 
the study. The estimated time of study completion per participant 
ranged between 30 and 35 min and did not differ between groups.
Definitions
For the primary analysis, high risk of progression was defined 
as the combination of a clinical relapse plus the presence of new 
brain lesions in follow-up magnetic resonance imaging (MRI) 
scans or at least one gadolinium-enhancing lesion (28, 29). All 
high-risk simulated clinical cases included a description of an 
MRI with more than five new T2 lesions or at least one enhanc-
ing lesion (30). The use of these definitions combining a clinical 
relapse and MRI activity is consistent with recent evidence 
regarding the risk of treatment failure among patients receiving 
interferon-β (31). Disease progression was defined as at least one 
point worsening from baseline in the Expanded Disability Status 
Scale score (32).
Recent meta-analysis confirmed that alemtuzumab, natali-
zumab, and fingolimod are the best available choices for preventing 
clinical relapses in patients with relapsing–remitting MS (RRMS) 
(33). The current treatment option for RRMS include first-line 
(beta interferons, glatiramer acetate), second-line (fingolimod), 
and third-line (natalizumab, alemtuzumab) therapies. For the 
present analysis, we used the aforementioned scheme according 
to the current clinical practice (4, 34, 35).
Outcome Measures
The primary feasibility outcome was the proportion of par-
ticipants who completed the study. A completion rate of 70% or 
higher was our pre-specified outcome. The feasibility of delivering 
the intervention was defined as the number of participants who 
correctly identified the “red traffic light” for clinical-scenarios 
comprising a high-risk of progression. A pre-specified criterion 
of at least 70% correct responses was used to classify the educa-
tional intervention as feasible.
Efficacy of the educational intervention, a secondary out-
come measure, was defined as a reduction in TI based on each 
individual response. We also evaluated secondary outcome the 
capability of the intervention to protect against decision fatigue 
decision fatigue [defined as the difference in TI within groups 
before (Block 1) and after the intervention (Block 2)] (36, 37). 
A significantly higher prevalence of TI in the 10 case-scenarios 
post-intervention (Block 2) would be indicative of decision 
fatigue.
Statistical analysis
Given the pilot nature of this study, we performed primarily 
descriptive statistics. We used non-parametric tests to compare 
continuous and categorical variables between groups. A Welch’s 
t-test was used to rule out large differences in TI. Logistic regres-
sion analysis was completed to determine the efficacy of the 
educational intervention in the reduction of TI after adjusting 
for responses in the pre-intervention period (Block 1).
We evaluated two different outcome measures: (i) TI defined 
as lack of treatment escalation in at least one case scenario and (ii) 
number of participants’ responses representing TI. We also com-
pared the total number of correct responses for each case-scenario 
between and within groups before and after the intervention. 
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FiGUrE 3 | Continued
Given our pre-specified target intervention, we compared the 
proportion of responses associated with TI between those who 
selected the “red light” in the active group vs. control group.
All tests were two-tailed, and p-values <0.05 were considered 
significant. We used STATA 13 (College Station, TX, USA: 
StataCorp LP) to conduct all analyses.
FiGUrE 3 | Educational intervention: the traffic light system may facilitate therapeutic decisions in multiple sclerosis care. Participants viewed the two informative 
panels (a,B) and a third panel providing an example (C).
TaBlE 1 | Baseline characteristics of participants.
Characteristics Total (%) 
n = 25
intervention 
(%) n = 11
Control (%) 
n = 14
Age (mean ± SD), in years 35.4 ± 7.3 33.8 ± 5.5 36.6 ± 8.4
Sex
Female 16 (64.0) 8 (72.7) 8 (57.1)
Specialty
Multiple sclerosis (MS) specialists 15 (60.0) 6 (54.6) 9 (64.3)
General neurologists who care for 
MS patients
10 (40.0) 5 (45.5) 5 (35.7)
Practice setting
Academic 22 (88.0) 11 (100) 11 (78.6)
Community 2 (8.0) 0 (0) 2 (14.3)
Both (academic and 
non-academic)
1 (4.0) 0 (0) 1 (7.1)
% time in clinical practice
Greater than 75% 16 (64.0) 6 (54.6) 10 (71.4)
Years in practice, mean (±SD) 9.9 ± 7.3 8.5 ± 5.0 11.1 ± 8.7
MS patients seen per week, mean 
(±SD)
17 ± 11.0 15.9 ± 10.5 17.8 ± 11.7
Attended latest ECTRIMS 
conference
14 (56.0) 5 (45.5) 9 (64.3)
Author of a peer-reviewed 
publication in the last 12 months
12 (48.0) 3 (27.3) 9 (64.3)
Numbers in brackets indicate percentages, unless otherwise indicated.
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rESUlTS
Of 30 neurologists from across Spain who were invited to partici-
pate in the study, 25 (83.3%) attended the meeting. Eleven par-
ticipants were randomly assigned to the educational intervention, 
whereas the remaining 14 were assigned to the control group.
Overall, the mean (SD) age was 35.4 (±7.3) years; 16 (64%) 
were females. Sixty percent (15/25) of participants primarily 
focused their practice on MS care. Table 1 summarizes baseline 
characteristics of the study population. Baseline characteristics 
appeared similar between groups. None of the participants 
choose to have a break.
The mean time to start the second set of cases post- 
randomization (block 2) was 12.7  s in the control group and 
11.8 s in the intervention group.
For the primary feasibility outcome, the completion rate of the 
study was 100% (25/25 participants). TI was present in 72.0% of 
participants in at least one case scenario. Only 4 (16%) partici-
pants did not exhibit TI (all case-scenarios were correct), whereas 
one-third of participants (8/25) exhibited TI in five or more simu-
lated case-scenarios. In the within-group analysis, we observed 
an increased prevalence of TI in the second set of case-scenarios 
(defined as decision fatigue) among participants in the control 
group (TI pre-intervention 57.1% vs. TI post-intervention 71.4%; 
p = 0.015), but not in the active group (TI pre-intervention 54.6% 
vs. TI post-intervention 63.6%; p = 0.14). Decision fatigue was 
associated with higher odds of TI (OR 3.99; 95% CI 1.05–15.1).
There was no TI block-by-intervention group interaction 
(p = 0.61). Comparative results between pre- and post-interven-
tion within and between groups are summarized in Table 2.
FiGUrE 4 | Prevalence of therapeutic inertia (TI) for the targeted intervention accounting for each individual response in the active and control groups. Lower 
numbers represent lower TI (more optimal therapeutic decisions). *p = 0.74, **p = 0.12. Note the lower trend in the prevalence of TI in the intervention group 
compared to the control group (22.6 vs. 33.9%; OR 0.57; 95% CI 0.26–1.22).
TaBlE 2 | Efficacy outcome measures: comparison pre- and post-intervention within and between groups.
intervention group Control group Comparison between 
groups
Efficacy outcomes Pre-
intervention
Post-
intervention
Change from  
pre-intervention  
(95% Ci)a
Pre-
intervention
Post-
intervention
Change from  
pre-intervention 
(95% Ci)a
Differences between 
groups post-intervention 
(95% Ci)b
n = 11 n = 11 n = 14 n = 14
Mean (SD) number of 
individual responses 
related to therapeutic 
inertia (TI)
1.91 (1.3) 2.36 (1.5) 0.45 (−2.20, 1.31) 2.14 (1.4) 2.71 (1.8) 0.57 (−2.61, 1.48) 0.35 (−1.01, 1.71)
Individual responses 
related to TI, n/N (%)
21/88 (0.24) 26/88 (0.30) 0.056 (−1.30, 1.41) 30/112 (0.27) 38/112 (0.34)  0.071 (−1.18, 1.32) 0.044 (−1.33, 1.42)
% (SD) of participants 
with TIc
54.5 (27.2) 63.6 (25.4) 9.1 (−14.2, 32.4) 57.1 (26.4) 71.4 (22.0) 14.3 (−4.5, 33.1) 7.80 (−12.2, 27.8)
n, number of responses related with TI; N, total number of responses. Numbers were rounded to two decimals.
aRepresents the difference and 95% CI in the efficacy outcomes between pre- and post-intervention within groups.
bRepresents the difference and 95% CI in the efficacy outcomes post-intervention between groups.
cTI identified in at least one case-scenario.
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Overall, 77.4% of participants correctly identified the “red 
traffic light” for clinical scenarios with high-risk of disease pro-
gression. Similarly, 86.4% of participants correctly identified the 
“yellow traffic light” for cases that would require a reassessment 
within 6–12  months. Thus, participants knew what should be 
done with different cases.
The analysis of each individual case-scenario revealed that TI 
was present in 23.9% of responses in the interventional group and 
26.8% of responses in the control group in the pre-intervention 
period (p = 0.74) (Figure 4). The multivariate analysis of each 
individual response revealed a non-significant reduction in TI 
in favor of the intervention group (OR 0.82; 95% CI 0.25–2.69) 
after adjusting for pre-intervention TI. The analysis evaluating 
individual responses targeted by the intervention (those cases 
where participants correctly identified the red light for high-
risk scenarios) revealed a non-significant reduction of TI in the 
10
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intervention group compared to the control group (OR 0.57; 95% 
CI 0.26–1.22) (Figure 4).
DiSCUSSiOn
Therapeutic inertia is a common phenomenon in the manage-
ment of patients with chronic medical conditions (2, 8). Moreover, 
there is limited information regarding educational interventions 
to overcome the effects of TI. In the present study, we used the 
well-defined paradigm of MS care, with its broad variability of 
therapeutic options to escalate treatment as a response to evi-
dence in disease activity.
We conducted a pilot randomized study allocating participat-
ing neurologists to an educational intervention (using the TLS) 
or usual care (control group). We found that TI was present in 
at least one case-scenario in 7 out of 10 participants. Overall, 
the great majority of participants correctly matched the traffic 
light (yellow and red) with the simulated case-scenario and 
appropriately escalated treatment. We found a non-significant 
43% reduction in the odds of TI by identifying the red traffic 
light. We also identified decision fatigue in the control group, 
but not in the intervention group. This finding suggests that 
the educational intervention may promote the continuity of 
accurate therapeutic decisions over time (by ameliorating the 
impact of decision fatigue on TI) despite the increasing number 
of case-scenarios.
The use of the TLS is a novel initiative to optimize decisions. 
It has been successfully applied to different medical fields, 
including the selection of healthier food choices leading to 
weight loss or the detection of children with fever at high risk 
of developing a serious bacterial infection (16, 18). Stangel and 
colleagues proposed the TLS to monitor treatment response 
in patients with RRMS. They included a more sophisticated 
scoring system (0–3) to categorize clinical relapses, evidence of 
disease progression, a cognitive assessment, and MRI findings. 
This scoring system leads to a decision model that uses the TLS 
to facilitate therapeutic choices (38). At the time of writing this 
manuscript, there were no data available on the application of 
this strategy.
Our study has some significant limitations. First, the sample 
size is small given the pilot design. As a consequence, our study 
was not powered to determine the efficacy of the educational 
intervention. Second, we used simulated case-scenarios that 
may not accurately reflect therapeutic decisions in clinical 
practice or known patients followed up over time. Third, 
some participants’ responses may reflect local limitations in 
the prescription of disease modifying agents. Fourth, we only 
tested some physician-level factors that may influence TI. 
Finally, we do not know if the educational intervention would 
require reinforcement months later to maintain its potential 
effect on TI.
Despite these limitations, our study suggests that a simple 
educational intervention applying the TLS is feasible to increase 
clinician’s recognition of MS patients at high risk of progression 
and overcome decision fatigue. Although our study evaluated 
therapeutic decisions in MS, the educational intervention could be 
applied to the management of other medical conditions and thus 
have wider-reaching implications for clinical care. Furthermore, 
our results serve as the basis for sample size calculations in the 
design of future studies.
Increasing awareness is the first step in the decision-making 
process to reduce the effects of TI. We used the TLS to increase 
awareness of treatment-relevant knowledge. Our study is also 
strengthened by: (i) a randomized design, (ii) the application of 
an evidence-based educational approach following the GREET 
guidelines (26), (iii) the implementation of a simple educational 
intervention that links to the neural pathways involved in 
decision-making under uncertainty (19, 27), and (iv) the target 
of a clinically relevant outcome (i.e., TI and decision fatigue) 
(4, 36) with the goal of overcoming knowledge-to-action gaps in 
MS treatment.
The next steps would include the implementation of studies at 
a larger scale to determine the efficacy of our educational inter-
vention in overcoming decision fatigue and reducing TI among 
primary care physicians and specialists managing patients with 
neurological (MS, stroke) and other chronic conditions (e.g., atrial 
fibrillation, diabetes).
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